Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
查看已审核书目、规范引用与获取指引。下载与积分规则登录后查看。
文献信息
题目
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
作者
S.-D. Hong, Y.-S. Wang, H.-Y. Zhao, Y.-Y. Zhao, Q.-M. Wang, Y.-X. Ma, Y.-S. Li, Y. Huang, Y.-P. Yang, Z.-M. Fu, L.-K. Chen, F. Zhou, J. Yang, X.-Y. Li, X. Hou, N.-N. Zhou, L.-H. Sun, G.-F. Zhang, J.-W. Cui, L. Wu, G. Chen, Y.-X. Zhang, H.-Y. Wang, D.-Q. Lv, J.-H. Shi, B. Jiang, C. Li, X.-L. Li, K.-J. Tang, Y. Yu, Y.-H. Ji, Z.-Y. He, Y. Zhu, H. Zhu, S. Xiao, C.-C. Zhou, L. Zhang, W.-F. Fang
Scihuhuan